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Summary 
It has recently been shown that open reading frames in the 3' long terminal repeats of mouse 
mammary tumor viruses encode superantigens. These viral superantigens (vSAGs) stimulate most 
T cells expressing appropriate V3s almost regardless of the rest of the variable components of 
the T cell receptors (TCR) expressed by those cells, vSAGs produce a type II integral membrane 
protein with a nonessential short cytoplasmic domain and a large glycosylated extracellular COOH- 
terminal domain, which is predicted to interact with major histocompatibility complex class 
II molecules and the TCR. The transmembrane region of vSAG also has an internal positively 
charged lysine residue of unknown significance. A set of chimeric and mutant vSAG genes has 
been used in transfection experiments to show that only the extreme COOH-terminal portion 
of vSAGs determine their TCR V3  specificities, and to show that the lysine residue in the 
transmembrane domain is not essential for the function of vSAG. 
S 
uperantigens (SAGs), combined with MHC class II mol- 
ecules, interact with a high proportion of TCR-o#3 (1, 
2).  This  high  frequency  of  interaction  occurs  because 
SAG-MHC  complexes stimulate virtually all  the T  cells 
bearing particular V3 elements almost irrespective of other 
variable components (Vtx, Jc~, and D/~J3) in TCtL (3-7). The 
recognition of SAG-MHC complexes by TCR is markedly 
different from the recognition of conventional peptide an- 
tigens, which require the contribution of both TCR o~ and 
chains (8-11). The unusual way in which SAG-MHC com- 
plexes interact with TCR has been partly explained by re- 
cent experiments showing that SAGs interact with the TCR 
primarily through the hypervariable region 4 (HVR4), well 
away from TCR-c~ and the third hypervariable region (12-14). 
Most murine endogenous SAGs are now known to be en- 
coded by the open reading frames (off) in the 3' LTR of mouse 
mammary tumor viruses (MMTV)  (15-22).  For example, 
Mls-1 antigen which stimulates T cells bearing V~ 6, 7, 8.1, 
and 9,  has been shown to be encoded by the off in the 3' 
LTR. of endogenous MMTV-7 (17, 23). MMTV-1, -3, -6, 
and -13 encode SAGs that stimulate T cells expressing V33 
elements (22). The off of different MMTVs are now termed 
viral  superantigens (vSAGs) (17, 18, 22-24).  For example, 
Mls-1 is denoted as vSAG-7 because the SAG is encoded by 
MMTV-7. 
It has recently been shown that vSAGs encode 45-kD glyo 
coproteins (23, 25, 26). The data provided by in vitro trans- 
lation experiments suggested that the vSAG produces a type 
II membrane protein with a large glycosylated extracellular 
COOH-terminal domain and a small, nonessential, intracel- 
lular NHz-terminal cytoplasmic domain (25, 26). With the 
use of mAb  specific for the COOH-terminal portion of 
vSAG-7,  it  has  been directly shown that  vSAG-7 indeed 
produces  a  membrane glycoprotein with  an  extracellular 
COOH-terminal domain (23). In addition, it has been shown 
that vSAGs are produced as 45-kD transmembrane precursor 
glycoproteins that are proteolytically processed to yield 18.5- 
kD surface proteins (23). However, it is still not clear whether 
this processed 18.5-kD polypeptide is sufficient for the func- 
tion of SAG, and whether the proteolytic cleavage of the pro- 
tein is essential for its function. 
The extensive sequence analysis of vSAG genes has shown 
that different vSAGs have very similar protein sequences with 
only 10-15% variation (16-18, 22). It is interesting that most 
sequence differences are located in two regions: polymorphic 
region I from amino acid residue 174 to 198, and region II 
from amino acid residue 288 to the COOH-terminus (see 
Fig. 1) (16-18, 22). For example, the amino acid residues in 
these two regions ofvSAG-1 (V/$3 associated) are very different 
from those ofvSAG-7 (V3 6, 7, 8.1, and 9 associated). How- 
ever, the sequences of polymorphic regions I and II ofvSAGs-1, 
-3, -5, and -13, which interact with TCR V33, are all iden- 
tical. This has led to the suggestion that these V regions are 
contributing to the TCR specificity of different vSAGs. An- 
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lysine residue in the transmembrane region (see Fig. 1). By 
analogy to the transmembrane region ofTCR c~ and B chains, 
it has been suggested that the lysine residue in the transmem- 
brahe region of the vSAG may contribute to the function 
of this protein (26,  27). 
To test the importance of polymorphic regions I and II 
of vSAG, and the importance of the lysine residue in the trans- 
membrane region for the superantigenic property of vSAG, 
we have constructed various chimeric and mutant vSAG genes 
and studied the properties of their protein products.  We re- 
port here that only polymorphic region II is important in 
determining the TCK VB specificity of the vSAG, and that 
the lysine residue in the transmembrane region is not essen- 
tial for the function  of this protein  as a superantigen. 
Materials  and  Methods 
Construction of Chimeric and Mutant vSAG Genes.  The vSAG-1 
and vSAG-7 genes have been described previously (22, 23). Chi- 
meric vSAG-ln7c and -7nlc series of genes were constructed by re- 
striction enzyme digestion and ligation of pTZ18K-vSAG-1 and -7 
(22, 23). The vSAG-7/KL was constructed by PCK-mediated, site- 
directed mutagenesis  as described previously (13, 14). 
The  primer  set of 5'-ATACTCATTCTCTGCTGCCTCCTT- 
GGCATA-Y (5' primer) and 5'-TATGCCAAGGAGGCAGCAGAG- 
AATGAGTAT-Y (3' primer) was used to replace the lysine residue 
to leucine residue. The mutant vSAGs were amplified with a set 
of primers  (5'-GGGAATTCTCGAGATGCCGCGCCTGCAG-Y 
and 5'-GGCd3ATCC'IL-WAGAGC.K;AACCG-3'),  cloned into pTZ18K 
(Pharmacia Fine Chemicals, Piscataway, NJ) or pBluescript KS § 
(Stratagene, La JoUa, CA), sequenced, and ligated into the mam- 
malian expression vector pHbAPr-1 as previously described (28). 
Transfection  ofvSAG Genes.  Wild-type vSAGs and their deriva- 
tive genes were linearized with PvuI and electroporated into the 
B cell lymphoma,  CH12.1, using a Gene Pulser Transfection Ap- 
paratus (Bio-Rad Laboratories, Cambridge, MA) at 240 V, 500 #F. 
The transfectants were selected by growth in G418 (700 #g/ml) 
and were screened for expression of transfected genes by Northern 
blot analysis or flow cytometric analysis using biotinyhted VS7 mAb 
as previously described (23). 
Assay of vSAG Function.  CH12.1 transfectants were screened 
for  their  ability  to  stimulate  the  T  cell  hybridomas  KMls-8 
(V~6 +) and 5KC-73.8 (V/33  +) because the vSAG-1 and vSAG-7 
are known to stimulate mouse T cells bearing these VBs, respec- 
tively. The T  cell hybridoma  KOX15-8.3  (V/315  +) was used as 
negative control (18). The stimulation  of T hybridomas was as- 
sayed by lymphokine  production  as previously described (29). 
Results  and  Discussion 
Regions of  vSAG Involved  in Determining TCR Vfl Specificity. 
The  sequence analysis  of vSAGs revealed  two regions  that 
are highly polymorphic among vSAGs (Fig.  1) (16-18, 22). 
For example, vSAG-7 and vSAG-1 have 46 amino acid res- 
idue differences,  of which eight residues are located in the 
polymorphic region  I  and 31  residues in the polymorphic 
region  II  (Fig.  1).  Based on  the  sequence comparison  of 
different vSAGs that have same the TCK VB specificity,  it 
was suggested that  polymorphic region I and/or  II would 
determine the TCK VB specificity of a given vSAG (16-18, 
22). To test this hypothesis directly, we have constructed sev- 
eral chimeric vSAGs from vSAG-1 and vSAG-7, VB3 and V/$6 
associated, respectively. The predicted amino acid sequences 
of vSAG-1 and vSAG-7 genes are shown in Fig.  1. 
There are three convenient restriction enzyme sites (BsmI, 
StuI, and PpuMI) at the same location in vSAG-1 and vSAG-7 
(Fig.  1). Therefore,  these restriction enzymes were used to 
generate chimeric vSAG genes, vSAG-ln7c, in which the gene 
fragment  5' to a restriction enzyme site was from vSAG-1 
and the gene fragment  3' to a restriction  enzyme site was 
from vSAG-7 (Fig. 2). These chimeric vSAG genes (named 
vSAG-ln7c-Bsm,  -Stu,  and -Ppu,  Fig.  2) were cloned into 
the mammalian expression vector, pHBAPr-1, and transfected 
into MHC class  II-expressing  CH12.1  lymphoma cells by 
electroporation.  Transfectants were assayed  for stimulation 
of T  cell hybridomas expressing VB3 and V/36,  the targets 
of vSAG-1 and vSAG-7,  respectively. 
The results of representative experiments are illustrated in 
Fig.  3.  As  previously  shown,  the  untransfected  cell  line, 
CH12.1,  failed to  stimulate  KMls-8  (V/36)  and  5KC-73.4 
(VB3)  (30,  31).  The  transfectants  expressing  vSAG-1, 
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The positions of  restriction enzyme sites are indi- 
cated. (*) Termination codon. (Shaded  boxes)  Por- 
tion from vSAG-1. (Solid  vertical  lines) Differences 
in  amino acid residues between vSAG-1 and 
vSAG-7. 
CH12.1/vSAG1-1, stimulated 5KC-73.4. Likewise, the trans- 
fectants  expressing  vSAG-7, CH12.1/vSAG7-A5C, stimulated 
KMls-8 (23). All the transfectants expressing chimeric vSAG- 
ln7c-Bsm, -Stu, and -Ppu (CH12.1/Bsm-1N7C.5,  CH12.1/ 
Stu-IN7C.9, and CH12.1/Ppu-lN7C.10,  respectively)  stimu- 
lated KMIs-8, hut  failed to stimulate  5KC-73.8.  A  V~15 + 
T  cell hybridoma,  KOX15-8.3,  was not  stimulated by any 
of the B cell lines,  as expected. Since vSAG-ln7c-Ppu is essen- 
tially identical to vSAG-1 except in polymorphic region II, 
the data provide direct evidence that the polymorphic region 
II of the vSAG-7 is sufficient to determine the VB specificity 
ofvSAG-7. These data also suggest that polymorphic region 
I is not involved in determining TCR V~/specificity of vSAG. 
Reciprocal experiments have also been done in this study, 
using the chimeric vSAG, vSAG-7nlcoPpu, in which the gene 
fragment 3' to the PpuI site in vSAG-1 is replaced with that 
in vSAG-7. The transfectants expressing the chimeric vSAG- 
7nlc-Ppu gene, CH12.1/Ppu-7N1C.1,  stimulated 5KC-73.8 
but not KMls-8, which is consistent with the data described 
above (Fig.  3). 
Is the Positively Charged Lysine Residue in the Transmembrane 
Region of the vSAG Essentialfor lts Function?  All the MMTV 
encoded vSAGs known  to date have an  internal  positively 
charged lysine residue in the transmembrane region (Fig.  1) 
(25, 26). By analogy to the transmembrane region of TCR 
c~ and ~/chains,  it has been proposed previously that the ly- 
Figure  3.  The importance of  polymorphic  region II in determining TCR 
V/3 specificity. CH12.1 cells transfected  with different vSAG  genes were 
tested for their ability to stimulate various T cell hybridomas, KMls-8 
(V/~8.1), 5KC-73.8 (V/~3), and KOX15-8.3 (V~15) as described  previously 
(18, 30, 31). Stimulation was assayed  24 h later by levels  of secreted lym- 
phokines in the supernatants. 
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Figure 4.  (A) Surface  expression  of vSAG-7 on cell lines. The cell  lines 
CH12.1, CH12.1/vSAG7-ASC,  and CH12.1/vSAG7-KL.1  were analyzed 
with VS7 antibody.  (Solid line) Flow cytometric  histogram  in the presence 
of peptides;  (broken  line with arrowheads)  flow cytometric  histogram  in the 
absence of peptides. (B) Effect of amino acid substitution lysine to leucine 
in the transmembrane  region on the superantigenic  activity of vSAG-7. 
The transfectants  expressing  similar  levels  of vSAG  on the cell surface  were 
tested for their ability to stimulate T cell hybridomas,  KMls-8 (V/~8.1). 
sine residue of vSAGs may have an important role in the func- 
tion of SAG, such as in the interaction of SAG with class 
II molecules (25,  26). 
To test this hypothesis, we have generated a mutant vSAG-7 
by changing the lysine residue to a leucine by site-directed 
mutagenesis. This mutant vSAG, vSAG-7/KL, was ligated 
into a  mammalian expression  vector and transfected  into 
CH12.1 cells as described above. The transfectants with similar 
surface vSAG-7 expression were selected and tested for their 
ability to stimulate T  cells. Representative experiments are 
shown in Fig. 4. The transfectant,  CH12.1/vSAG7-KL.1,  ex- 
pressing the mutant vSAG-7, stimulated KMIs-8 as efficiently 
as CH12.1/vSAG7-A5C, which expresses wild-type vSAG-7. 
These data suggest that the internal positively charged ly- 
sine residue in the transmembrane region of vSAG-7 is not 
essential for its function. Since the transfectants expressing 
similar surface levels of wild-type and mutant vSAG stimu- 
lated KMls-8 with approximately the same efficiency, it is 
also unlikely that the lysine residue is involved in the interac- 
tion of vSAG antigen with MHC class II molecules. 
The experiments in this study have conclusively  shown 
that only polymorphic region II at the extreme COOH- 
terminus of vSAGs determines the TCR VB specificity of 
a given vSAG. Polymorphic region I of vSAG is not involved 
in determining the TCR V3 specificity. However, possible 
involvement of polymorphic region I for the function of vSAG 
is not excluded as yet. Since chimeric vSAGs of different poly- 
morphic regions I and II produce functional proteins, it seems 
unlikely that polymorphic region I interacts directly with 
amino acid residues in polymorphic region II which interact 
with the V~ element of TCR. It has been noticed for some 
time that different vSAGs show variable degrees of stimula- 
tion of target T  cells in mixed lymphocyte reactions,  even 
though all vSAGs are very efficient in clonal deletion of target 
T cells during T cell development in the thymus (1-7). There- 
fore, it is possible that polymorphic region I may be involved 
in presentation of vSAG to T  cells, either by affecting  the 
interaction of vSAGs with MHC class II molecules or the 
transport of vSAG to the cell surface. 
By making a mutant vSAG-7 lacking an internal positively 
charged residue in the transmembrane region, we have shown 
that the lysine residue at position 51 is not important for 
the surface expression of vSAG. Since the mutant vSAG stimu- 
lated target T  cells as efficiently as the wild-type vSAG, it 
is unlikely that the lysine residue is involved in the associa- 
tion of vSAG with MHC class II molecules, which is a pre- 
requisite  for the stimulation of T  cells by vSAG. 
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